Sandoz weighed down by legal costs in the first half of the year
Keystone-SDA
Swiss generic drugs giant Sandoz saw profits plummet by 70% in the first six months of the year as a result of huge legal costs.
Profits slumped to $109 million after the company was fined around $480 million in the United States.
The Rhine-based multinational had previously set aside provisions for this anticipated legal cost.
The half-yearly report published on Wednesday also lists restructuring costs of $54 million, costs relating to empowerment of $47 million, costs for optimising production facilities of $41 million and software deployment costs of $33 million.
Turnover grew by 10% in US dollars, or 5% in local currencies, to $5.76 billion. This performance was driven in particular by a 25% rise in revenue from biosimilars, to $1.86 billion.
Revenue from the core generics business stabilised, falling by 1% in local currencies but rising by 4% when converted into US dollars, to $3.89 billion. Attributed to disruptions in the penicillin market, the decline stood at 3% over the first three months of the year
The share of biosimilars in turnover thus reached 33%, compared with 29% 12 months earlier, the Rhineland-based multinational highlighted in its half-yearly report.
On the profitability front, earnings before interest, tax, depreciation and amortisation (EBITDA), adjusted for any items deemed non-recurring, jumped by 15% to $1.21 billion, driven by an increase of around 90 basis points to 20.9%. Basic net profit rose by 18% to $750 million.
The figures presented are more or less in line with the forecasts of analysts surveyed by AWP.
More
More
Swiss pharma firm Sandoz to pay $450m in US antitrust suit
+ How we produce English news
Translated from French, reviewed by an English Department journalist.
